Envisagenics, Inc.
Envisagenics is a biotechnology company focused on transforming RNA insights into therapeutic impact through its AI platform, SpliceCore®. The company specializes in discovering novel, disease-specific RNA splicing targets for developing safer and more effective treatments in oncology and neurodegeneration. With a collaborative, patient-driven team, Envisagenics aims to unlock the untapped potential of RNA splicing to create breakthrough therapies.
Industries
Nr. of Employees
small (1-50)
Envisagenics, Inc.
Long Island City, New York, United States, North America
Products
AI platform for discovery of disease-specific RNA splicing targets
A software platform that analyzes transcriptomic data to discover novel, prevalent splicing events that are disease-specific and suitable for therapeutic targeting.
Machine learning module for neoepitope identification
A computational module for predicting tumor-specific neoepitopes generated by alternative splicing to enable immunotherapy target selection.
Preclinical therapeutic candidate programs (oncology and CNS)
A portfolio of preclinical programs targeting RNA splicing events across oncology indications and central nervous system disorders, progressed from in silico discovery through experimental validation.
AI platform for discovery of disease-specific RNA splicing targets
A software platform that analyzes transcriptomic data to discover novel, prevalent splicing events that are disease-specific and suitable for therapeutic targeting.
Machine learning module for neoepitope identification
A computational module for predicting tumor-specific neoepitopes generated by alternative splicing to enable immunotherapy target selection.
Preclinical therapeutic candidate programs (oncology and CNS)
A portfolio of preclinical programs targeting RNA splicing events across oncology indications and central nervous system disorders, progressed from in silico discovery through experimental validation.
Services
Collaborative research partnerships
Research collaborations and development agreements with academic and industry partners to co-develop discovery or validation programs.
Experimental target validation and preclinical support
Wet-lab validation services and preclinical development support to confirm and advance computationally identified splicing targets.
Collaborative research partnerships
Research collaborations and development agreements with academic and industry partners to co-develop discovery or validation programs.
Experimental target validation and preclinical support
Wet-lab validation services and preclinical development support to confirm and advance computationally identified splicing targets.
Expertise Areas
- Splicing-based target discovery
- RNA biology and RNA-targeted therapeutics
- Immuno-oncology neoepitope discovery
- Neurodegenerative disease target discovery
Key Technologies
- Machine learning / AI for genomics
- Transcriptomic (RNA‑seq) analysis
- High-performance computing and cloud analytics
- Neoepitope prediction algorithms